Article
Building novel binding ligands to B7.1 and B7.2 based on human antibody single variable light chain domains.
Journal of molecular biology - 13 Jul 2001
van den Beucken T, van Neer N, Sablon E, Desmet J, Celis L, Hoogenboom H R, Hufton S E
Abstract excerpt
Ligands specific for B7.1 (CD80) and B7.2 (CD86) have applications in disease indications that require inhibition of T-cell activity. As we observed significant sequence and structural similarity between the B7-binding ligand, cytotoxic T-lymphocyte associated protein-4 (CTLA-4), and antibody variable light chain domains (VLs), we have explored the possibilities of making novel B7 binding molecules based on...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.